Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

Humacyte, Inc. (HUMA) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.53%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq appreciated by 0.52%. Heading into today, shares of the company had lost 5.03% over the past month, lagging the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71%.The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of -$0.17, indicating a 48.48% growth compared to the equivalent quarter last year. HUMA's full-year Zacks Consensus Estimates are calling for earnings of -$0.35 per share and revenue of $3.51 million. These results would represent year-over-year changes of +66.67% and 0%, respectively. Investors should also take note of any recent adjustments to analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Humacyte, Inc. is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks